The U.S. Senate gave unanimous approval to a bipartisan bill to “cut the red tape” that stalls scientific research into the medical properties of cannabis and cannabidiols.
According to a news release issued Thursday by U.S. Sen. Dianne Feinstein, a California Democrat, the Senate approved S. 253 on a voice vote.
The measure – which would authorize the U.S. Food and Drug Administration to study cannabis products – now heads to the U.S. House of Representatives for consideration.
The bill was co-sponsored by Iowa Republican Sen. Chuck Grassley and Hawaii Democrat Brian Schatz, who both lauded the bill’s success.
“This bipartisan bill … will empower the FDA to analyze CBD and medical marijuana products in a safe and responsible way so that the American public can decide whether to utilize them in the future based on sound scientific data.”
The Senate measure comes almost a year after the U.S. Drug Enforcement Administration signaled it might ease its restrictions on marijuana research.
Medical Disclaimer:
The information provided in these blog posts is intended for general informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. The use of any information provided in these blog posts is solely at your own risk. The authors and the website do not recommend or endorse any specific products, treatments, or procedures mentioned. Reliance on any information in these blog posts is solely at your own discretion.
